| Literature DB >> 33354650 |
Aastha Mishra1, Shankar Chanchal1, Mohammad Z Ashraf1.
Abstract
Severe novel corona virus disease 2019 (COVID-19) infection is associated with a considerable activation of coagulation pathways, endothelial damage, and subsequent thrombotic microvascular injuries. These consistent observations may have serious implications for the treatment and management of this highly pathogenic disease. As a consequence, the anticoagulant therapeutic strategies, such as low molecular weight heparin, have shown some encouraging results. Cytokine burst leading to sepsis which is one of the primary reasons for acute respiratory distress syndrome (ARDS) drive that could be worsened with the accumulation of coagulation factors in the lungs of COVID-19 patients. However, the obscurity of this syndrome remains a hurdle in making decisive treatment choices. Therefore, an attempt to characterize shared biological mechanisms between ARDS and thrombosis using comprehensive transcriptomics meta-analysis is made. We conducted an integrated gene expression meta-analysis of two independently publicly available datasets of ARDS and venous thromboembolism (VTE). Datasets GSE76293 and GSE19151 derived from National Centre for Biotechnology Information-Gene Expression Omnibus (NCBI-GEO) database were used for ARDS and VTE, respectively. Integrative meta-analysis of expression data (INMEX) tool preprocessed the datasets and effect size combination with random effect modeling was used for obtaining differentially expressed genes (DEGs). Network construction was done for hub genes and pathway enrichment analysis. Our meta-analysis identified a total of 1,878 significant DEGs among the datasets, which when subjected to enrichment analysis suggested inflammation-coagulation-hypoxemia convolutions in COVID-19 pathogenesis. The top hub genes of our study such as tumor protein 53 (TP53), lysine acetyltransferase 2B (KAT2B), DExH-box helicase 9 (DHX9), REL-associated protein (RELA), RING-box protein 1 (RBX1), and proteasome 20S subunit beta 2 (PSMB2) gave insights into the genes known to be participating in the host-virus interactions that could pave the way to understand the various strategies deployed by the virus to improve its replication and spreading. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ).Entities:
Keywords: ARDS; COVID-19; SARS-COV-2; inflammation; thrombosis
Year: 2020 PMID: 33354650 PMCID: PMC7746517 DOI: 10.1055/s-0040-1721706
Source DB: PubMed Journal: TH Open ISSN: 2512-9465
Fig. 1Flow diagram depicting the selection of microarray meta-analysis and characteristics of individual studies included in the study. ARDS, acute respiratory distress syndrome, GEO, gene expression omnibus; VTE, venous thromboembolism.
Fig. 2Result illustrations of comprehensive transcriptomics meta-analysis between acute respiratory distress syndrome (ARDS) and venous thromboembolism (VTE) using integrative meta-analysis of expression data (INMEX) tool ( A ) Plot of principal component analysis (PCA) as validation tool before batch effect removal and ( B ) after batch effect removal (using Combat method). ( C ) The Venn diagram comparing differentially expressed genes (DEGs) sets identified by the individual studies and by meta-analysis. The results obtained by the meta-analysis (1,878 DEGs) are compared with DEGs identified by individual study of VTE and ARDS. ( D ) Network depicting zero-order interaction of the shared DEGs in between ARDS and VTE datasets. Among the top 20 hub genes, few selected hub genes known to participate in host-viral interaction are shown in purple (overexpressed genes) and yellow (underexpressed gene) colors using Cytoscape. ( E ) Overrepresentation of pathways and gene ontology categories in biological networks identified from meta-analysis. Network representations of enriched pathway integrating the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome pathways along with Gene ontology for the selected top 20 hub genes using ClueGO Cytoscape plug-in. Hyper-geometric enrichment distribution tests, with an adjusted p -value of ≤0.05, followed by the Bonferroni adjustment for the terms and term groups were selected based on the highest significance.
Enrichment analysis of the shared DEGs in the meta-analysis according to Kobas3.0
| Pathway ID | Enriched pathway | Database | Input no. | Background no. |
|
|---|---|---|---|---|---|
| R-HSA-449147 | Signaling by interleukins | Reactome | 92 | 619 | 3.51E-30 |
| R-HSA-3700989 | Transcriptional regulation by TP53 | Reactome | 71 | 359 | 4.07E-30 |
| R-HSA-109582 | Hemostasis | Reactome | 78 | 617 | 7.22E-22 |
| R-HSA-1257604 | PIP3 activates AKT signaling | Reactome | 48 | 247 | 1.55E-20 |
| R-HSA-5633007 | Regulation of TP53 activity | Reactome | 37 | 159 | 2.29E-18 |
| R-HSA-913531 | Interferon signaling | Reactome | 39 | 194 | 2.15E-17 |
| R-HSA-449836 | Other interleukin signaling | Reactome | 43 | 275 | 1.57E-15 |
| R-HSA-446652 | Interleukin-1 family signaling | Reactome | 29 | 138 | 9.83E-14 |
| R-HSA-877300 | Interferon gamma signaling | Reactome | 23 | 90 | 1.10E-12 |
| R-HSA-9020702 | Interleukin-1 signaling | Reactome | 23 | 101 | 8.36E-12 |
| R-HSA-76002 | Platelet activation, signaling and aggregation | Reactome | 34 | 260 | 1.08E-10 |
| R-HSA-1169091 | Activation of NF-κβ in B cells | Reactome | 18 | 66 | 1.25E-10 |
| P00031 | Inflammation mediated by chemokine and cytokine signaling | PANTHER | 29 | 201 | 3.24E-10 |
| R-HSA-1234174 | Cellular response to hypoxia | Reactome | 18 | 74 | 6.08E-10 |
| P00036 | Interleukin signaling | PANTHER | 18 | 80 | 1.78E-09 |
| R-HSA-1234176 | Oxygen-dependent proline hydroxylation of hypoxia-inducible factor alpha | Reactome | 16 | 65 | 4.67E-09 |
| hsa04621 | NOD-like receptor signaling | KEGG | 25 | 178 | 8.51E-09 |
| hsa04657 | Interleukin -17 signaling | KEGG | 18 | 93 | 1.39E-08 |
| R-HSA-9020591 | Interleukin-12 signaling | Reactome | 13 | 47 | 4.02E-08 |
| R-HSA-447115 | Interleukin-12 family signaling | Reactome | 14 | 57 | 4.36E-08 |
| P00047 | PDGF signaling | PANTHER | 19 | 124 | 1.51E-07 |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | Reactome | 17 | 108 | 4.80E-07 |
| R-HSA-8950505 | Gene and protein expression by JAK-STAT signaling after interleukin-12 stimulation | Reactome | 10 | 38 | 2.17E-06 |
| R-HSA-448424 | Interleukin-17 signaling | Reactome | 11 | 72 | 6.26E-05 |
| R-HSA-6783783 | Interleukin-10 signaling | Reactome | 8 | 47 | 0.000324 |
| hsa04610 | Complement and coagulation cascades | KEGG | 10 | 79 | 0.000523 |
| R-HSA-1059683 | Interleukin-6 signaling | Reactome | 4 | 11 | 0.001037 |
| R-HSA-9008059 | Interleukin-37 signaling | Reactome | 5 | 21 | 0.0012 |
| R-HSA-8984722 | Interleukin-35 signaling | Reactome | 4 | 12 | 0.001348 |
| R-HSA-6783589 | Interleukin-6 family signaling | Reactome | 5 | 24 | 0.002002 |
| R-HSA-5660668 | CLEC7A/inflammasome | Reactome | 3 | 6 | 0.002313 |
| R-HSA-8854691 | Interleukin-20 family signaling | Reactome | 5 | 25 | 0.002341 |
| P00011 | Blood coagulation | PANTHER | 6 | 38 | 0.00253 |
| R-HSA-2162123 | Synthesis of prostaglandins (PG) and thromboxanes (TX) | Reactome | 4 | 15 | 0.002662 |
| P00030 | Hypoxia response via HIF activation | PANTHER | 5 | 26 | 0.002719 |
| R-HSA-448706 | Interleukin-1 processing | Reactome | 3 | 8 | 0.004333 |
| R-HSA-451927 | Interleukin-2 family signaling | Reactome | 6 | 44 | 0.004852 |
| R-HSA-9020933 | Interleukin-23 signaling | Reactome | 3 | 9 | 0.005641 |
| R-HSA-512988 | Interleukin-3, interleukin-5 and GM-CSF signaling | Reactome | 6 | 47 | 0.006471 |
| R-HSA-9020956 | Interleukin-27 signaling | Reactome | 3 | 11 | 0.008903 |
| R-HSA-1234158 | Regulation of gene expression by hypoxia-inducible factor | Reactome | 3 | 11 | 0.008903 |
| R-HSA-912526 | Interleukin receptor SHC signaling | Reactome | 4 | 26 | 0.014291 |
| R-HSA-2022377 | Metabolism of angiotensinogen to angiotensins | Reactome | 3 | 18 | 0.027605 |
| R-HSA-1266695 | Interleukin-7 signaling | Reactome | 4 | 36 | 0.037224 |
| hsa04614 | Renin-angiotensin system | KEGG | 3 | 23 | 0.048055 |
Abbreviations: AKT, α serine/threonine-protein kinase; DEG, differentially expressed genes; GM-CSF, gross motor-cerebrospinal fluid; HIF, hypoxia-inducible factor; KEGG, Kyoto encyclopedia of genes and genomes; NF, nuclear factor; NOD, nucleotide-binding, oligomerization domain; PDGF, platelet-derived growth factor; JAK-STAT, janus kinase-signal transducer and activator of transcription; CLEC7A, C-type lectin domain containing 7A; SHC, Src homology 2 domain; PIP3, phosphatidylinositol (3,4,5)-trisphosphate.
Note: Input number signifies the number of hits from the meta-analysis whereas background number is from each curated gene set library. Pathways in the table were ranked based on the adjusted p-value.
Top twenty hub genes prioritized based on the topological parameters, that is, degree using Cytoscape
| Entrez ID | Symbol | Degree | Betweenness centrality | Closeness centrality | Combined ES |
|
|---|---|---|---|---|---|---|
| 7157 | TP53 | 60 | 0.294336 | 0.369736 | −1.6588 | 0 |
| 7314 | UBB | 39 | 0.202782 | 0.349528 | 0.4802 | 0.02506 |
| 3320 | HSP90AA1 | 31 | 0.193582 | 0.352381 | 0.7022 | 0.00034 |
| 207 | AKT1 | 30 | 0.133454 | 0.342366 | −1.847 | 0.000224 |
| 983 | CD1 | 27 | 0.052607 | 0.318769 | 0.65994 | 0.000892 |
| 8850 | KAT2B | 24 | 0.0692 | 0.32134 | 0.6207 | 0.001954 |
| 10594 | PRPF8 | 23 | 0.033761 | 0.255172 | −1.5438 | 0 |
| 4088 | SMAD3 | 22 | 0.075699 | 0.31318 | −1.3522 | 5.34E-12 |
| 998 | CDC42 | 20 | 0.0827 | 0.289547 | 0.73897 | 0.005455 |
| 3184 | HNRNPD | 20 | 0.035921 | 0.27364 | −0.82441 | 0.000317 |
| 1457 | CSNK2A1 | 19 | 0.11239 | 0.315661 | −0.51181 | 0.015109 |
| 1660 | DHX9 | 18 | 0.087967 | 0.290685 | −0.43831 | 0.047395 |
| 5970 | RELA | 18 | 0.080218 | 0.323144 | −1.4588 | 2.12E-13 |
| 9978 | RBX1 | 17 | 0.019157 | 0.272202 | 1.5674 | 0 |
| 5710 | PSMD4 | 16 | 0.002551 | 0.266324 | 0.80414 | 3.19E-05 |
| 5706 | PSMC6 | 16 | 9.23E-04 | 0.267286 | 0.44812 | 0.041198 |
| 5690 | PSMB2 | 16 | 0.00169 | 0.267286 | −0.48723 | 0.022315 |
| 220988 | HNRNPA3 | 16 | 0.001619 | 0.239482 | −0.5779 | 0.004609 |
| 6429 | SRSF4 | 16 | 0.005126 | 0.239593 | −0.82971 | 1.67E-05 |
| 5591 | PRKDC | 16 | 0.055064 | 0.324765 | −1.1922 | 6.3E-10 |
Abbreviations: AKT1, α serine/threonine-protein kinase 1; CD1, cyclin-dependent 1; DHX9, DExH-box helicase 9; ES, effect size; HSP90AA1, heat shock protein 90 alpha family class-A member 1; KAT2B, lysine acetyltransferase 2B; PSMB2, proteasome 20S subunit beta; PSMD4, proteasome 26S subunit, non-ATPase 4; RBX1, RING-box protein 1; RELA, REL-associated protein; TP53, total protein 53; UBB, ubiquitin B; PRPF8, pre-mRNA-processing-splicing factor 8; CDC42, cell division control protein 42 homolog; HNRNPD, heterogeneous nuclear ribonucleoprotein D; CSNK2A1, casein kinase II subunit alpha; PSMC6, proteasome 26S subunit, ATPase 6; HNRNPA3, heterogeneous nuclear ribonucleoprotein A3; SRSF4, serine and arginine rich splicing factor 4; PRKDC, protein kinase, DNA-activated, catalytic subunit.
Note: Expression level (combined ES) and p-value was added from the meta-analysis in the table. The highlighted ones are the genes known to participate in host-viral interactions.
Fig. 3Diagrammatic illustration of host-viral interactions of some of the hub genes that came out from our network-based meta-analysis. The host–virus interactions participation of some of our hub genes is suggestive that these pathological conditions strengthens a favorable environment for virus and further aids in aggravating its viral load and deterioration of patients. ACE2, angiotensin-converting enzyme 2; CDK1, cyclin dependent kinase 1; DHX9, DExH-box helicase 9; IKK, i-κ-kinase; KAT2B, lysine acetyltransferase 2B; NF-κβ, nuclear factor kappa B; P21/CDK, P21/cyclin-dependent kinase; PSMB2, proteasome β subunits 2 family; PSME3, proteasome activator complex subunit 3; RBX1, RING-box protein 1; RELA, REL-associated protein; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; TLR2, toll-like receptor 2; TMPRSS2, transmembrane serine protease 2; TP53, tumor protein 53; WRAP53, WD repeat containing antisense to TP53.